Compare RAPP & INNV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RAPP | INNV |
|---|---|---|
| Founded | 2022 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Nursing Services |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2024 | 2021 |
| Metric | RAPP | INNV |
|---|---|---|
| Price | $28.59 | $8.89 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 6 | 1 |
| Target Price | ★ $48.50 | $7.00 |
| AVG Volume (30 Days) | 318.5K | ★ 325.8K |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.34 | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | ★ $853,699,000.00 |
| Revenue This Year | N/A | $12.85 |
| Revenue Next Year | N/A | $8.88 |
| P/E Ratio | ★ N/A | $59.89 |
| Revenue Growth | N/A | ★ 11.76 |
| 52 Week Low | $7.73 | $2.60 |
| 52 Week High | $42.27 | $10.69 |
| Indicator | RAPP | INNV |
|---|---|---|
| Relative Strength Index (RSI) | 48.89 | 55.15 |
| Support Level | $26.67 | $5.01 |
| Resistance Level | $29.84 | $9.18 |
| Average True Range (ATR) | 1.98 | 0.65 |
| MACD | -0.17 | -0.19 |
| Stochastic Oscillator | 42.40 | 27.17 |
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.